| http://www.w3.org/ns/prov#value | - nt programs and obtain regulatory approval for Feraheme/Rienso in the broader IDA indication both in the US and outside of the US, including the EU, (4) the possibility that significant safety or drug interaction problems could arise with respect to Feraheme/Rienso and in turn affect sales, regulatory approval, or our ability to market the product both in the U.S. and outside of the U.S., includin
|
